Invent Medic Sweden Valuation
Is IMS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of IMS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von IMS für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von IMS für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IMS?
Other financial metrics that can be useful for relative valuation.
What is IMS's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | kr32.94m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 5.1x |
Enterprise Value/EBITDA | -4.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does IMS's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 9.6x | ||
BIOVIT Bio Vitos Pharma | 23.2x | n/a | kr69.4m |
BIOWKS Bio-Works Technologies | 3.5x | n/a | kr154.0m |
S2M S2Medical | 2.4x | n/a | kr21.5m |
OSSD OssDsign | 9.2x | 24.3% | kr1.0b |
IMS Invent Medic Sweden | 4.9x | n/a | kr32.9m |
Price-To-Sales gegen Gleichaltrige: IMS ist ein guter Wert, wenn man sein Price-To-Sales Verhältnis (5.9x) mit dem Durchschnitt der anderen Unternehmen (8.7x) vergleicht.
Price to Earnings Ratio vs Industry
How does IMS's PE Ratio compare vs other companies in the SE Medical Equipment Industry?
Price-To-Sales gegen Industrie: IMS ist teuer, wenn man sein Price-To-Sales Verhältnis (4.9x) mit dem Swedish Medical Equipment Branchendurchschnitt (4.3x) vergleicht.
Price to Sales Ratio vs Fair Ratio
What is IMS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 4.9x |
Fair PS Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Sales Fair Ratio von IMS für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.